Stockscreener 앱 받기
22.04
2.13%
-0.48
시간 외 거래:
22.04
전일 마감가:
$22.52
열려 있는:
$22.06
하루 거래량:
347.13K
Relative Volume:
1.20
시가총액:
$684.70M
수익:
-
순이익/손실:
$-62.26M
주가수익비율:
-9.5772
EPS:
-2.3013
순현금흐름:
$-53.80M
1주 성능:
-0.85%
1개월 성능:
+13.03%
6개월 성능:
+512.22%
1년 성능:
+687.14%
1일 변동 폭
$20.94
$22.52
1주일 범위
$20.94
$25.17
52주 변동 폭
$1.60
$25.17
Alto Neuroscience Inc Stock (ANRO) Company Profile
명칭
Alto Neuroscience Inc
전화
773-255-5012
주소
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
22.04 | 699.61M | 0 | -62.26M | -53.80M | -2.3013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-11-17 | 개시 | BTIG Research | Buy |
| 2025-09-29 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-23 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-09-03 | 개시 | Wedbush | Outperform |
| 2024-02-27 | 개시 | Jefferies | Buy |
| 2024-02-27 | 개시 | Robert W. Baird | Outperform |
| 2024-02-27 | 개시 | Stifel | Buy |
| 2024-02-27 | 개시 | TD Cowen | Outperform |
| 2024-02-27 | 개시 | William Blair | Outperform |
모두보기
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Alto Neuroscience, Inc. (ANRO) and Pfizer (PFE) - The Globe and Mail
Alto Neuroscience Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Canada
Stifel reiterates Buy on Alto Neuroscience stock, $33 target - Investing.com
Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating - TipRanks
Alto Neuroscience (NYSE:ANRO) Stock Price Down 3.6%Time to Sell? - MarketBeat
ANRO: ALTO-207 advances in TRD with rapid titration, strong efficacy, and key pipeline catalysts ahead - TradingView
Chardan Capital Reiterates "Buy" Rating for Alto Neuroscience (NYSE:ANRO) - MarketBeat
Alto Neuroscience (NYSE:ANRO) Price Target Raised to $22.00 - MarketBeat
$120M financing supports Alto’s precision neuroscience approach to TRD - The Pharmaletter
Alto raises $120m for resistant depression programme - pharmaphorum
Alto Neuroscience raises $120M to fund depression drug trial By Investing.com - Investing.com South Africa
Alto Neuroscience Reports Strong 2025 Financials, Advances Precision Psychiatry Pipeline with ALTO-207 Acquisition and Key Clinical Milestones - Minichart
Alto Neuroscience Secures $120 Million Private Placement to Fund Phase 3 Study of ALTO-207 for Treatment Resistant Depression - Minichart
Targeting depression, Alto Neuroscience raises $120 million - The Business Journals
Watkins Advises on Alto Neuroscience’s US$120 Million Private Placement Financing - Latham & Watkins LLP
Alto Neuroscience 2025 Annual Report: Precision Psychiatry Platform, Clinical Pipeline, and Intellectual Property Overview - Minichart
Alto Neuroscience, Inc. announced that it expects to receive $119.99969 million in funding from a group of investors - marketscreener.com
Jefferies raises Alto Neuroscience stock price target on pipeline By Investing.com - Investing.com Canada
Alto Neuroscience (NYSE:ANRO) Sets New 1-Year HighHere's Why - MarketBeat
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum - marketscreener.com
Alto Neuroscience (ANRO) Reports FY25 Loss of $2.19/Share - AlphaStreet
Alto Neuroscience Announces $120 Million Private Placement Financing - TradingView
Alto Neuroscience raises $120M to fund depression drug trial - Investing.com
Alto Neuroscience Secures $120 Million Private Placement Financing - TipRanks
Alto Neuroscience (NYSE:ANRO) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Alto Neuroscience (NYSE: ANRO) secures $120M PIPE to fund ALTO-207 - Stock Titan
ANRO: ALTO-207 acquisition and robust cash support multiple pivotal trials through 2028 - TradingView
Alto Neuroscience (NYSE: ANRO) outlines broad precision psychiatry pipeline and IP - Stock Titan
Alto Neuroscience 10-K: Net loss $63.24M, EPS $(2.19) - TradingView
Alto Neuroscience (NYSE: ANRO) posts 2025 loss but extends cash runway to 2028 - Stock Titan
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights - Yahoo Finance
Alto Neuroscience (ANRO) to Release Quarterly Earnings on Thursday - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading 7.3% HigherWhat's Next? - MarketBeat
Alto Neuroscience Stock Pre-Market (-7.0%): Geopolitical Tensions Spark Risk-Off Move - Trefis
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
VSE Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday - Intellectia AI
Alto Neuroscience (NYSE:ANRO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Market Review: What are Alto Neuroscience Incs earnings expectationsPortfolio Profit Report & Low Drawdown Momentum Ideas - baoquankhu1.vn
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Fed Meeting: Is Alto Neuroscience Inc benefiting from interest rate changesDay Trade & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ANRO Stock Price, Quote & Chart | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill
Alto Neuroscience (NYSE:ANRO) Stock Price Down 7.2%What's Next? - MarketBeat
Alto Neuroscience Stock Quote, Share Price, News and Analysis - Longbridge
Alto Neuroscience (NASDAQ: ANRO) CEO has shares withheld for taxes - Stock Titan
Alto Neuroscience (ANRO) CFO reports 2,806-share tax withholding - Stock Titan
ANRO: ALTO-207 and ALTO-101 advance with biomarker-driven trials and improved formulations for mental health - TradingView
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week HighShould You Buy? - MarketBeat
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - Benzinga
Alto Neuroscience Inc (ANRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):